Zacks: Brokerages Set $10.00 Price Target for Ekso Bionics Holdings, Inc. (EKSO)

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) has earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Analysts have set a 12-month consensus price objective of $10.00 for the company and are predicting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also assigned Ekso Bionics an industry rank of 117 out of 265 based on the ratings given to its competitors.

Several equities analysts recently issued reports on EKSO shares. ValuEngine upgraded Ekso Bionics from a “strong sell” rating to a “sell” rating in a research note on Friday, November 17th. Zacks Investment Research cut Ekso Bionics from a “buy” rating to a “hold” rating in a research note on Wednesday, September 6th.

Ekso Bionics (NASDAQ:EKSO) opened at $2.13 on Tuesday. Ekso Bionics has a one year low of $0.99 and a one year high of $4.77. The stock has a market capitalization of $127.60, a price-to-earnings ratio of -1.88 and a beta of -0.07. The company has a debt-to-equity ratio of 0.18, a quick ratio of 5.73 and a current ratio of 6.09.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.05). Ekso Bionics had a negative return on equity of 323.00% and a negative net margin of 343.53%. The firm had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.40 million. analysts predict that Ekso Bionics will post -0.81 EPS for the current fiscal year.

In other Ekso Bionics news, insider Russ Angold sold 50,000 shares of the firm’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $3.51, for a total value of $175,500.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 3.32% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. National Planning Corp increased its holdings in shares of Ekso Bionics by 122.2% during the third quarter. National Planning Corp now owns 520,942 shares of the company’s stock valued at $620,000 after purchasing an additional 286,492 shares during the period. Intellectus Partners LLC increased its holdings in shares of Ekso Bionics by 5.3% during the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after purchasing an additional 5,294 shares during the period. Carl Domino Inc increased its holdings in shares of Ekso Bionics by 125.2% during the third quarter. Carl Domino Inc now owns 184,788 shares of the company’s stock valued at $224,000 after purchasing an additional 102,734 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Ekso Bionics by 32.9% during the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after purchasing an additional 176,197 shares during the period. Institutional investors own 6.22% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Set $10.00 Price Target for Ekso Bionics Holdings, Inc. (EKSO)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.com-unik.info/2017/12/26/zacks-brokerages-set-10-00-price-target-for-ekso-bionics-holdings-inc-ekso.html.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Get a free copy of the Zacks research report on Ekso Bionics (EKSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit